Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of product and services sales, net (1) | 97.1 | 66.9 | 169.1 | 155.4 |
| Research and development | 9.2 | 12.5 | 19.7 | 27.6 |
| Selling, general and administrative | 44.6 | 43.7 | 91.2 | 96.1 |
| Amortization of intangible assets | 17.2 | 16.2 | 33.7 | 32.5 |
| Impairment of long-lived assets | 191.3 | — | 191.3 | — |
| Total operating expenses | 359.4 | 139.3 | 505.0 | 311.6 |
| Income (loss) from operations | (125.1) | 1.6 | (114.6) | 51.5 |
| Other income (expense): |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's D&A?
- Emergent Biosolutions (EBS) reported D&A of $17.2M in Q2 2026.
- How has Emergent Biosolutions's D&A changed year-over-year?
- Emergent Biosolutions's D&A increased by 6.2% year-over-year, from $16.2M to $17.2M.
- What is the long-term trend for Emergent Biosolutions's D&A?
- Over 4 years (2021 to 2025), Emergent Biosolutions's D&A has grown at a 2.7% compound annual growth rate (CAGR), from $58.5M to $65.1M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Emergent Biosolutions's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude